Worldwide, 20 million people are infected with HTLV-1, a majority of which remain asymptomatic carriers (ACs) while others develop ATL or HAM/TSP with no effective treatment, vaccine or cure. The exact mechanism(s) of disease pathophysiology remain unresolved with a big question of high proviral load in HAM/TSP patients despite vigorous cellular immune response (primarily directed towards viral transactivator protein Tax)? Our initial studies implicated programmed death (PD)-1 receptor and its ligand, PD-L1 as potential underlying factors for observed immune cells' dysfunctions leading to viral persistence and disease progression, primarily in HAM/TSP patients. PD-1:PD-L1/PD-L2 are the members of immunoglobulin superfamily (IgSF) co-signaling molecules and have been linked with CD8 T-cell exhaustion during chronic viral infections. Several members of this family play critical role in regulating antigen-specific immune responses, and it is becoming increasingly evident that blocking multiple inhibitory receptors simultaneously improves T-cell based therapies. Therefore, we propose to investigate a comparative co-expression pattern of key IgSF negative regulators among carriers versus patients followed by standardizing of a blockade strategy to restore polyfunctionality, immune homeostasis, and cytolytic potential of antigen-specific T cells in HTLV-1 patient cohorts. To project advantage, this kind of therapeutic measure has shown promising results in other human diseases; however, it needs to be evaluated with respect to neuroinflammatory diseases especially those associated with chronic infection for which HTLV-1 provides a good model. While this approach should help in restoring functions of pre-existing antiviral immunity in patients, activating new CTLs to mimic polyclonal CD8 T-cell response found in ACs will be the key for a successful immunotherapeutic intervention of HTLV-associated diseases. Thus, we will identify a panel of HTLV-1 epitopes directly from the infected cells and validate in ACs to select potential neoepitopes capable of initiating a polyclonal response in chronically infected patients. The selected candidates from both approaches will then be coupled in a combined immunotherapy, which will be evaluated pre-clinically in a humanized (BLT) mouse model of HTLV-1 chronic infection. Our central hypothesis is that a combined immunotherapy coupled with immune checkpoint blockers and neo-epitopes derived from infected cells will restore existing T-cell functions while expanding protective CTLs in chronically infected patients. As a result of this, HTLV-1 proviral load and concomitant Tax expression will be reduced leading to decreased antigen threshold for the expansion of T cells with dysregulated functions and exhausted phenotype. The restoration of positive immunity within periphery will also lead to the reduced accumulation of activated T cells and inflammation within the CNS potentially ameliorating the disease. These studies will strengthen the potential of immunotherapeutic treatment options for HTLV-1 and will impact our understanding of other chronic infectious diseases of broader impact such as those associated with HBV, HCV, HIV-1, etc.

Public Health Relevance

These studies will investigate approaches to restore immune cell functions and enhance protective anti-viral immunity during HTLV-associated diseases. This proposal also intends to accelerate the pre-clinical development of a novel emerging vaccine strategy, which could prevent significant complications of chronic HTLV-1 infection. Additional information derived will facilitate the development of novel immunotherapeutic initiatives to treat HTLV-induced neuroinflammatory disease as well as those of other etiologies.

National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Research Project (R01)
Project #
Application #
Study Section
NeuroAIDS and other End-Organ Diseases Study Section (NAED)
Program Officer
Wong, May
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Drexel University
Schools of Medicine
United States
Zip Code
Sharma, Ravi Kumar; Sharma, Jyoti; Khan, Zafar K et al. (2018) Diminished TLR2-TLR9 mediated CD4+ T cell responses are associated with increased inflammation in intraocular tuberculosis. Sci Rep 8:13812
Dave, Rajnish S; Jain, Pooja; Byrareddy, Siddappa N (2018) Functional Meningeal Lymphatics and Cerebrospinal Fluid Outflow. J Neuroimmune Pharmacol 13:123-125
Mulherkar, Ria; Karabudak, Aykan; Ginwala, Rashida et al. (2018) In vivo and in vitro immunogenicity of novel MHC class I presented epitopes to confer protective immunity against chronic HTLV-1 infection. Vaccine 36:5046-5057
Dave, Rajnish S; Jain, Pooja; Byrareddy, Siddappa N (2018) Follicular Dendritic Cells of Lymph Nodes as Human Immunodeficiency Virus/Simian Immunodeficiency Virus Reservoirs and Insights on Cervical Lymph Node. Front Immunol 9:805
Dave, Rajnish S; Sharma, Ravi K; Muir, Roshell R et al. (2018) FDC:TFH Interactions within Cervical Lymph Nodes of SIV-Infected Rhesus Macaques. J Neuroimmune Pharmacol 13:204-218
Ginwala, Rashida; Caruso, Breanna; Khan, Zafar K et al. (2017) HTLV-1 Infection and Neuropathogenesis in the Context of Rag1-/-?c-/- (RAG1-Hu) and BLT Mice. J Neuroimmune Pharmacol 12:504-520
Pestell, Timothy G; Jiao, Xuanmao; Kumar, Mukesh et al. (2017) Stromal cyclin D1 promotes heterotypic immune signaling and breast cancer growth. Oncotarget 8:81754-81775
Sagar, Divya; Singh, Narendra P; Ginwala, Rashida et al. (2017) Antibody blockade of CLEC12A delays EAE onset and attenuates disease severity by impairing myeloid cell CNS infiltration and restoring positive immunity. Sci Rep 7:2707
Pustylnikov, Sergey; Dave, Rajnish S; Khan, Zafar K et al. (2016) Short Communication: Inhibition of DC-SIGN-Mediated HIV-1 Infection by Complementary Actions of Dendritic Cell Receptor Antagonists and Env-Targeting Virus Inactivators. AIDS Res Hum Retroviruses 32:93-100
Ginwala, Rashida; McTish, Emily; Raman, Chander et al. (2016) Apigenin, a Natural Flavonoid, Attenuates EAE Severity Through the Modulation of Dendritic Cell and Other Immune Cell Functions. J Neuroimmune Pharmacol 11:36-47